MindWalk (HYFT)
Combines biological context, AI software, and wet-lab research for drug discovery.
Something off on this page? Send us feedback.
Combines its HYFT biological representation, LensAI software, ReefIQ data layer, and wet-lab capabilities for AI-enabled discovery. LensAI is used in contracted, recurring arrangements, while the platform links client discovery data to AI-reasoning workflows.
Builds AI-enabled discovery infrastructure that combines its HYFT biological representation, LensAI software, ReefIQ data layer, and wet-lab capabilities. LensAI is used in contracted, recurring arrangements, and ReefIQ is described as the biological-context layer between client discovery data and AI-reasoning workflows.
The 2025 rebrand unified the former ImmunoPrecise Antibodies business with BioStrand and Talem under one brand. After divesting its Netherlands operation, the organization concentrated resources on BioNative AI and selected wet-lab programs, connecting multi-omics data, laboratory research, and AI workflows as a single platform. This connects software with laboratory execution.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| May 20, 2026 | H.C. Wainwright | Target | $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Apr 30, 2026Cash & short-term investments $8.2M · Total debt $2.5M · Total assets $15.5M · Shareholders' equity $8.5M
- Revenue
- $3.0M
- Operating income
- −$3.1M
- Net income
- —
Reported in CAD, converted at the latest exchange rate
No dividends on record.
| Institutions28 holders · as of Mar 31, 2026 | 9.68% | 4.52M ADS | |
| Otherremainder | 90.32% | 42.19M ADS |
46.71M ADS as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ingalls & Snyder LLCInstitution | 6.22% | 2.91M ADS | 13Fas of Mar 31, 2026 |
Susquehanna International Group, LLPInstitution | 1.14% | 534,016 ADS | 13Fas of Mar 31, 2026 |
Renaissance Technologies LLCInstitution | 0.50% | 232,480 ADS | 13Fas of Mar 31, 2026 |
XTX Topco LtdInstitution | 0.37% | 172,547 ADS | 13Fas of Mar 31, 2026 |
Citadel Advisors LLCInstitution | 0.32% | 147,907 ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Twist Bioscience
Antibody-discovery services spanning AI and wet-lab workflows
- Absci
Generative-AI biologics design with wet-lab validation
- Recursion Pharmaceuticals
AI-native, full-stack drug discovery and development platform
- Schrödinger
Physics-plus-AI computational molecular-discovery platform
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MindWalk | $1.36 | +4.62% | $62.7M | — | — | 5.6 | −40.1% |
| Twist Bioscience | $130.01 | −0.76% | $8.16B | — | — | 18.9 | +23.3% |
| Absci | $8.83 | +0.29% | $1.49B | — | — | 955.0 | −49.4% |
| Recursion Pharmaceuticals | $3.38 | +0.15% | $1.77B | — | — | 32.3 | −61.8% |
| Schrödinger | $20.72 | −0.77% | $1.56B | — | — | 6.0 | +7.5% |
| Median | — | — | 25.6 | −20.9% |